International journal of clinical oncologyHumansFemaleBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesRetrospective Studies
Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.
Zhenhua Fan, Yang Yuan, Xiaoyan Chen, Tao Wang, Shaohua Zhang, Li Bian, Xueli Mo
Published: 202510.1007/s10147-025-02887-y
Abstract
BACKGROUND: No clinical trials demonstrated anti-HER2 plus chemotherapy (anti-HER2 + ChT) was superior to anti-HER2 plus endocrine therapy (anti-HER2 + ET) in HR + /HER2 + MBC. This study aims to compare efficacy of anti-HER2 + ET with anti-HER2 + Ch…
Preview only. Read the full abstract at the source